Geocann is first-to-market introducing cannabigerol (CBG) formulations utilizing the VESIsorb® drug delivery system
23 août 2019 11h00 HE
|
Geocann
FORT COLLINS, Colo., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Geocann is proud to announce that the company has successfully commercialized the first cannabigerol (CBG) soft gel products that utilize the...
Relevium’s Biocannabix Executes LOI to Acquire 30% Interest in Weedsense, a Late Stage Applicant for Standard Processing and Medical Sales License
05 juin 2019 09h46 HE
|
Relevium Technologies Inc
MONTREAL, June 05, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly owned...
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums
09 avr. 2019 09h35 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC:AXIM), a world leader in cannabinoid research and development, today...
New U.S. Patent Issuance Granted to AXIM® Biotechnologies for Oral Care Composition Containing Cannabinoids
29 janv. 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Jan. 29, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the...
Relevium Engages PipeDreemz as Lead ACMPR Consultant for Biocannabix
17 mai 2018 08h00 HE
|
Relevium Technologies Inc
MONTREAL, May 17, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce it has engaged PipeDreemz as...
Relevium Creates Biocannabix Subsidiary and Targets Legal Cannabis Business
19 avr. 2018 10h14 HE
|
Relevium Technologies Inc
MONTREAL, April 19, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX VENTURE:RLV) (OTCQB:RLLVF) (FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce the creation of...
AXIM Biotechnologies Reports Second Quarter 2017 Results
22 août 2017 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, Aug. 22, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced results for the quarter...
Axim® Biotechnologies, Inc. Donates Flagship CanChew Gum to U.S. Pain Foundation to Help Chronic Pain Sufferers
22 nov. 2016 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has donated...
New U.S. Patent Allowance Granted to AXIM® Biotech for Use of All Cannabinoids in Its Controlled-Release Chewing Gum Products
16 nov. 2016 09h00 HE
|
AXIM Biotechnologies, Inc
NEW YORK, Nov. 16, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in hemp cannabinoid research and development, today announced that the United...
AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
17 mai 2016 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 17, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical...